Rheumatoid Arthritis

This study applied a validated algorithm to estimate the effectiveness and costs of the index biologic used by 4696 US veterans with rheumatoid arthritis.

Test diagnoses RA with better accuracy by detecting synthetic citrullinated peptides.

Excess production of tumor necrosis factor causes both RA and the onset of heart valve disease.

Submission bolstered by trials evaluating biosimilar candidate in moderate-to-severe plaque psoriasis and rheumatoid arthritis.

Research finds patients are not staying on methotrexate long enough before switching to more costly biologic drugs.

Tofacitinib effective in the treatment of moderate to severe atopic dermatitis.

Positive mood throughout daily life linked to less pain and fewer RA-related restrictions.

Treatment with sarilumab improves RA signs, symptoms, and physical function.

Baricitinib improved disease activity in patients not responding to conventional or biologic DMARDs.

Biosimilar may offer patients with RA drug cost relief in the near future.

Experimental DMARD may be clinically beneficial for active rheumatoid arthritis treatment.

Risk of death in patients with cardiovascular and respiratory conditions amplified in female patients with rheumatoid arthritis.

Strategy reduces cost without compromising RA symptom control.

Many RA treatments suppress the immune system, leaving patients at risk for contracting a potentially fatal infection.

Pfizer asked to provide additional safety analyses for proposed indication.

Research may improve the diagnosis of infectious and autoimmune diseases, including rheumatoid arthritis and HIV.

RA patients carry myocardial and vascular abnormalities even in the earlier stages of disease progression.

Study finds ultrasound should be included in the management of RA patients in clinical remission.

Varying prevalence of fatigue from RA has been reported due to differences in definitions and measures.

Arava can reduce RA symptoms and slow down associated structural damage.

Shoulder muscle strength found to decrease even in early stage RA patients.

Treatment shows rapid and significant improvements in signs and symptoms of RA after 24 weeks of treatment.

Clinical signs and symptoms of RA may be preceded by a preclinical phase lasting several years.

Lymphoma and lung cancer present significant risk to RA patients.

Birth control use not found to impact disease progression.